... system to improve NK cell immunotherapy for acute myeloid leukemia (AML).The aim is to prevent relapses and reduce animal testing with mimicking models.
“By combining adaptive NK cells with a bispecific NK cell engager, we demonstrate how innate immune mechanisms can be harnessed to achieve effective and well-tolerated anti-tumor responses in multiple myeloma.”.
"By combining adaptive NK cells with a bispecific NK cell engager, we demonstrate how innate immune mechanisms can be harnessed to achieve effective and well-tolerated anti-tumor responses in multiple myeloma.".
...CellTherapyMarket ... However, short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.